ARIAD Pharmaceuticals, Inc. is an oncology company founded in 1991 and headquartered in Cambridge, Massachusetts. On December 14, 2012 the FDA approved Ariad Pharmaceutical's leukemia drug Iclusig for patients with all forms of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or unable to tolerate other tyrosine kinase therapies on the market. The drug was temporarily withdrawn from the market in November 2013 "because of the risk of life-threatening blood clots and severe narrowing of blood vessels". This suspension was partially lifted on Dec. 20, 2013 with ponatinib being issued revised prescribing information, a new "Black Box Warning" and a "Risk Evaluation and Mitigation Strategy" in place to better evaluate the risks and be

Property Value
dbo:abstract
  • ARIAD Pharmaceuticals, Inc. is an oncology company founded in 1991 and headquartered in Cambridge, Massachusetts. On December 14, 2012 the FDA approved Ariad Pharmaceutical's leukemia drug Iclusig for patients with all forms of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or unable to tolerate other tyrosine kinase therapies on the market. The drug was temporarily withdrawn from the market in November 2013 "because of the risk of life-threatening blood clots and severe narrowing of blood vessels". This suspension was partially lifted on Dec. 20, 2013 with ponatinib being issued revised prescribing information, a new "Black Box Warning" and a "Risk Evaluation and Mitigation Strategy" in place to better evaluate the risks and benefits of using the drug. Ariad also has brigatinib, a lung cancer drug which has completed its registration trial in ALK fusion driven non-small cell lung cancer as of June 2016. (en)
dbo:assets
  • 50.4
dbo:foundingYear
  • 1991-01-01 (xsd:date)
dbo:industry
dbo:location
dbo:netIncome
  • 85.25
dbo:numberOfEmployees
  • 125 (xsd:integer)
dbo:operatingIncome
  • 104.9
dbo:product
dbo:revenue
  • 178.98
dbo:type
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 20737471 (xsd:integer)
dbo:wikiPageRevisionID
  • 724270338 (xsd:integer)
dbp:keyPeople
  • Chairman of the Board
  • President of Research and Development and Chief Scientific Officer
  • Alex Denner,
  • CEO since December 2016
  • Harvey Berger,
  • Paris Panayiotopoulos ,
  • Timothy P. Clackson,
  • retired Chairman & CEO
dbp:logo
  • 151 (xsd:integer)
dbp:slogan
  • Leading the pathway to better cancer therapies
dct:subject
rdf:type
rdfs:comment
  • ARIAD Pharmaceuticals, Inc. is an oncology company founded in 1991 and headquartered in Cambridge, Massachusetts. On December 14, 2012 the FDA approved Ariad Pharmaceutical's leukemia drug Iclusig for patients with all forms of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or unable to tolerate other tyrosine kinase therapies on the market. The drug was temporarily withdrawn from the market in November 2013 "because of the risk of life-threatening blood clots and severe narrowing of blood vessels". This suspension was partially lifted on Dec. 20, 2013 with ponatinib being issued revised prescribing information, a new "Black Box Warning" and a "Risk Evaluation and Mitigation Strategy" in place to better evaluate the risks and be (en)
rdfs:label
  • ARIAD Pharmaceuticals (en)
owl:sameAs
prov:wasDerivedFrom
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • ARIAD Pharmaceuticals, Inc. (en)
is dbo:wikiPageRedirects of
is foaf:primaryTopic of